VOLUME 22 | NUMBER 10 | OCTOBER 2016 nature medicine l e t t e r S The MYCN proto-oncogene is amplified in a number of advanced-stage human tumors, such as neuroblastomas. Similar to other members of the MYC family of oncoproteins, MYCN (also known as N-Myc) is a transcription factor, and its stability and activity are tightly controlled by ubiquitinationdependent proteasome degradation [1] [2] [3] [4] . Although numerous studies have demonstrated that N-Myc is a driver of neuroblastoma tumorigenesis, therapies that directly suppress N-Myc activity in human tumors are limited. Here we have identified ubiquitin-specific protease 7 (USP7; also known as HAUSP) 5-7 as a regulator of N-Myc function in neuroblastoma. HAUSP interacts with N-Myc, and HAUSP expression induces deubiquitination and subsequent stabilization of N-Myc. Conversely, RNA interference (RNAi)-mediated knockdown of USP7 in neuroblastoma cancer cell lines, or genetic ablation of Usp7 in the mouse brain, destabilizes N-Myc, which leads to inhibition of N-Myc function. Notably, HAUSP is more abundant in patients with neuroblastoma who have poorer prognosis, and HAUSP expression substantially correlates with N-Myc transcriptional activity. Furthermore, small-molecule inhibitors of HAUSP's deubiquitinase activity markedly suppress the growth of MYCN-amplified human neuroblastoma cell lines in xenograft mouse models. Taken together, our findings demonstrate a crucial role of HAUSP in regulating N-Myc function in vivo and suggest that HAUSP inhibition is a potential therapy for MYCN-amplified tumors.
l e t t e r S
The MYCN proto-oncogene is amplified in a number of advanced-stage human tumors, such as neuroblastomas. Similar to other members of the MYC family of oncoproteins, MYCN (also known as N-Myc) is a transcription factor, and its stability and activity are tightly controlled by ubiquitinationdependent proteasome degradation [1] [2] [3] [4] . Although numerous studies have demonstrated that N-Myc is a driver of neuroblastoma tumorigenesis, therapies that directly suppress N-Myc activity in human tumors are limited. Here we have identified ubiquitin-specific protease 7 (USP7; also known as HAUSP) [5] [6] [7] as a regulator of N-Myc function in neuroblastoma. HAUSP interacts with N-Myc, and HAUSP expression induces deubiquitination and subsequent stabilization of N-Myc. Conversely, RNA interference (RNAi)-mediated knockdown of USP7 in neuroblastoma cancer cell lines, or genetic ablation of Usp7 in the mouse brain, destabilizes N-Myc, which leads to inhibition of N-Myc function. Notably, HAUSP is more abundant in patients with neuroblastoma who have poorer prognosis, and HAUSP expression substantially correlates with N-Myc transcriptional activity. Furthermore, small-molecule inhibitors of HAUSP's deubiquitinase activity markedly suppress the growth of MYCN-amplified human neuroblastoma cell lines in xenograft mouse models. Taken together, our findings demonstrate a crucial role of HAUSP in regulating N-Myc function in vivo and suggest that HAUSP inhibition is a potential therapy for MYCN-amplified tumors.
Originally, the ubiquitin-proteasome pathway was thought to work as 'a one-way street' from substrate ubiquitination to degradation by the 26S proteasome. However, the finding that HAUSP interacts with, and deubiquitinates, the complex of the tumor suppressor protein p53 (encoded by Trp53 in mice and TP53 in humans) and the MDM2 oncoprotein was one of the first examples that deubiquitinases (DUBs) have a specific role in regulating protein stability [5] [6] [7] .
A substantial body of research indicates that HAUSP regulates both p53-dependent and p53-independent signaling networks. Further supporting this notion, HAUSP modulates the stability and activity of several cellular factors [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Nevertheless, it remains unclear which cellular factor(s) might contribute to the neonatal lethality of Nes-Cre;Usp7 fl/fl (hereafter referred to as Nes-Cre;Hausp fl/fl ) conditionalknockout mice 18 , in which Cre recombinase, expressed under the control of the nestin gene (Nes) promoter, mediates deletion of loxP-flanked (floxed) Hausp exon 6, resulting in production of a truncated catalytically inactive protein. Here we sought to identify novel substrates of HAUSP that are outside of the p53 network and that specifically control embryonic cell growth and development of the mouse brain. N-Myc, which regulates cell cycle progression and neuronal differentiation and which predominantly functions during embryogenesis, emerged as an attractive candidate 1, 2, 19, 20 . Notably, the conventional Mycn-knockout mouse [21] [22] [23] shows embryonic lethality, whereas the Nes-Cre-driven conditional knockout of Mycn 24 has a decrease in cerebellar and cerebral cortex mass due to defective cellular proliferation, which is similar to the effect seen in mice in which the floxed Hausp gene is deleted by expression of Nes-Cre 18 .
To examine a potential relationship between HAUSP and N-Myc, the mouse cortex was analyzed; HAUSP depletion markedly stabilized p53 ( Fig. 1a and Supplementary Fig. 1a ), consistent with previous results 18 . Unexpectedly, N-Myc levels in Nes-Cre;Hausp fl/fl mice were lower than those in Hausp fl/fl littermate controls ( Fig. 1a and Supplementary Fig. 1a ). This decline in the N-Myc protein level was independent of transcriptional regulation, as no obvious changes in MYCN mRNA levels were detected ( Supplementary  Fig. 1b ). Moreover, immunohistochemical staining revealed that N-Myc levels were reduced in the Hausp-knockout tissues (Fig. 1b) ; notably, this effect on N-Myc protein levels caused by the Hausp knockout remained the same in the Trp53-null background (Fig. 1b) . Taken together, our data suggest that HAUSP controls N-Myc protein levels in vivo regardless of p53 status.
To dissect the precise role of HAUSP in regulating N-Myc, we first examined the interaction between HAUSP and N-Myc. To this end, we transfected HEK293 cells with a construct expressing N-Myc either alone or with one expressing Flag-tagged HAUSP. Western blot analysis revealed that N-Myc was detected in HAUSP immunoprecipitates ( Fig. 1c) , similarly to that seen with the p53 control ( Supplementary Fig. 1c ). In the reciprocal experiment, HAUSP was detected in N-Myc immunoprecipitates (Supplementary Fig. 1d ). To elucidate this interaction in a physiological setting, cell extracts from the neuroblastoma cancer cell lines IMR-32 (which has wildtype (WT) TP53) and SK-N-BE(2)C (which has mutated TP53) were immunoprecipitated with the HAUSP-specific antibody. Endogenous N-Myc was readily detected in the anti-HAUSP immunoprecipitates from both cell lines, irrespective of p53 status, but not with those using the control IgG ( Fig. 1d,e ). To test whether this interaction is direct, we performed an in vitro glutathione-S-transferase (GST) pulldown assay with highly purified GST-tagged HAUSP and Flag-tagged N-Myc recombinant proteins. We found that N-Myc bound to immobilized GST-HAUSP but not to GST alone ( Fig. 1f and Supplementary Fig. 1e ). To further validate the direct interaction, we performed the reciprocal in vitro binding assay by using bacterially produced GST-N-Myc and purified Flag-HAUSP. Western blot analysis revealed that HAUSP indeed bound to GST-N-Myc but not to GST ( Fig. 1g) . To map the minimal domain of N-Myc that is critical for the interaction with HAUSP, we generated N-Myc deletion mutants to narrow down the binding site ( Fig. 1h) . By using coimmunoprecipitation assays we found that HAUSP is present in the immunoprecipitates containing hemagglutinin (HA)-tagged I  II  III   III   III   III   III   IV   IV   IV  I  II   I  II   I  II   124   280   345   381   BR-HLH-LZ   BR-HLH- l e t t e r S full-length N-Myc (amino acids 1-464), N-Myc(∆1-123), N-Myc(∆382-464), N-Myc(∆346-464) and N-Myc(281-464) ( Fig. 1i and Supplementary Fig. 1f ). In contrast, HAUSP was not detected in the immunoprecipitates containing HA-N-Myc(∆281-464) by the same approach. These data demonstrate that the small region of N-Myc containing amino acids 281-345 is crucial for the binding to HAUSP (Fig. 1h) . Further analyses showed that these observed differences in binding were not caused by differential subcellular localizations of HAUSP and the N-Myc mutant proteins ( Supplementary Fig. 1g,h) . Sequence analysis also revealed that this region (amino acids 281-345) shares very low sequence homology with c-Myc-much less than the highly conserved MYC box regions ( Supplementary Fig. 1i ), underscoring the specificity of HAUSP with N-Myc, as compared c-Myc.
To understand the functional consequence of the HAUSP-N-Myc interaction, we first examined whether HAUSP expression affects N-Myc protein levels and found that the levels of N-Myc increased after HAUSP overexpression ( Fig. 2a and Supplementary Fig. 2a ). Notably, HAUSP overexpression was able to stabilize both N-Myc(∆382-464) and N-Myc(∆346-464) but not N-Myc(∆281-464) in the same assay ( Fig. 2b) , suggesting that direct interaction is required for HAUSP-mediated stabilization of N-Myc. Moreover, catalytically inactive HAUSP (HAUSP CS ) had a markedly reduced effect on N-Myc stabilization (Fig. 2c) , independently of affecting MYCN mRNA ( Supplementary Fig. 2b ), suggesting that HAUSP regulates N-Myc stability through its deubiquitinase activity. Consistent with this conclusion, the half-life of N-Myc was markedly extended in the presence of HAUSP WT but not HAUSP CS or an empty expression vector ( Fig. 2d and Supplementary Fig. 2c ). Next we sought to determine whether HAUSP is indeed able to catalyze deubiquitination of N-Myc in cells and observed that the high levels of ubiquitinated N-Myc were markedly reduced after overexpression of WT but not HAUSP CS ( Fig. 2e) . Collectively, these results demonstrate that N-Myc is a bona fide substrate of HAUSP.
The removal of ubiquitin and subsequent stabilization of N-Myc suggests that HAUSP prevents N-Myc degradation. Therefore, we reasoned that ablation of HAUSP may drive N-Myc proteolysis. We used a MYCN-amplified neuroblastoma cell line, SK-N-DZ, to ablate endogenous HAUSP levels ( Fig. 2f) . Reducing HAUSP expression by RNAi (using a pool of four HAUSP-specific oligonucleotides decreased N-Myc protein levels; moreover, the levels of N-Myc were consistently decreased by using each of the four individual oligonucleotides comprising the HAUSP RNAi pool, excluding off-target effects (Fig. 2f) ; MYCN mRNA levels remained unaffected after HAUSP knockdown ( Supplementary Fig. 2d ). Similar results were obtained by using other MYCN-amplified neuroblastoma cell lines, such as LAN-1 and SK-N-BE(2)C ( Fig. 2f) . Many studies indicate that neuroblastoma cells have a crucial dependency on N-Myc expression for cell proliferation 4, 25 . Indeed, HAUSP knockdown suppressed incorporation of 5-bromo-2′-deoxyuridine (BrdU), a marker for cell proliferation, in a manner analogous to that for MYCN knockdown in both SK-N-DZ and IMR-32 cells ( Supplementary Fig. 2e,f) . Moreover, SK-N-DZ cells that expressed a HAUSP-specific short hairpin RNA (shRNA) ( Supplementary Fig. 2g ) showed a significant growth defect as compared to control SK-N-DZ cells that expressed a green fluorescent protein gene (GFP)-specific shRNA ( Fig. 2g) , without any detectable signs of apoptosis ( Supplementary Fig. 2h,i ). Finally, we tested whether HAUSP could affect the oncogenic properties of neuroblastoma cells; HAUSP knockdown in SK-N-DZ cells suppressed colony formation ( Fig. 2h and Supplementary Fig. 2j ). Collectively, these data implicate that HAUSP is critical for both the stability and activity of endogenous N-Myc in neuroblastoma cells.
Although their spatial and temporal expression differs, N-Myc is closely related to c-Myc in structure and function 19, 20 ; therefore, we investigated whether HAUSP ablation also affects c-Myc stability. To examine the effects of HAUSP on c-Myc and N-Myc in the same cellular context, we generated a TP53-null lung carcinoma cell line (H1299) that stably expresses an exogenous N-Myc polypeptide (Supplementary Fig. 3a ). HAUSP knockdown reduced N-Myc levels but had no obvious effect on c-Myc levels (Fig. 2i) ; similar results were obtained in parental H1299 cells and in the human colon cancer cell line HCT116 (Supplementary Fig. 3b ). Moreover, in mouse embryonic fibroblasts generated from the Nes-Cre;Hausp fl/fl embryos, depletion of HAUSP did not alter the expression levels of npg l e t t e r S endogenous c-Myc (Supplementary Fig. 3c ). Consistent with this, HAUSP knockdown had no obvious cell growth defects in native H1299 cells ( Supplementary Fig. 3d,e ). Finally, unlike with N-Myc, HAUSP was unable to remove the ubiquitin moieties from c-Myc (Supplementary Fig. 3f) . These data suggest that HAUSP-mediated effects are specific for N-Myc but not c-Myc.
Recent studies have described small molecules that specifically inhibit HAUSP deubiquitination activity in vivo and in vitro 8, [26] [27] [28] [29] . To further extend our findings, we tested whether HAUSP-mediated stabilization of N-Myc is also suppressed by HAUSP-specific inhibitors. We first determined whether the deubiquitinase activity of HAUSP on N-Myc is indeed suppressed by the inhibitor. The ability of HAUSP to remove ubiquitin moieties from N-Myc was completely blocked by treatment with the commercially available HAUSP inhibitor P22077 (ref. 27) ( Fig. 3a) . Similar results were also obtained with another specific HAUSP inhibitor, P5091 (ref. 29) , (Supplementary Fig. 4a ). Using a panel of neuroblastoma cell lines, we demonstrated that treatment with either P22077 (Fig. 3b, top) or P5091 (Fig. 3b, bottom) destabilizes N-Myc protein levels without significantly altering MYCN mRNA levels (Supplementary Fig. 4b,c) . Similar to knocking down HAUSP, P22077 treatment did not affect c-Myc ubiquitination or protein levels ( Supplementary Fig. 4d,e) . Consistently, the reduction of N-Myc protein levels was reverted by addition of the proteasome inhibitor MG132 (Fig. 3c) , without affecting MYCN mRNA (Supplementary Fig. 4f ), suggesting that treatment with the HAUSP inhibitor promotes N-Myc proteolysis, similar to the effect observed after HAUSP knockdown. Because NB-16-derived tumors grow faster in the subcutaneous model than SK-N-DZ-derived tumors, treatment started 2 weeks after implantation, whereas with the SK-N-DZ-derived tumors treatment began 3 weeks after implantation to have a tumor size more similar to that of NB-16-derived tumors at the start of treatment. Both SK-N-DZ and NB-16 subcutaneous models were treated with the same dose of P22077 for the same amount of time ( Supplementary Fig. 6g ).
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Moreover, the functional consequence that HAUSP has on neuroblastomas through the regulation of N-Myc was examined by analyzing BrdU incorporation and cell growth assays. Indeed, treatment with P22077 reduced the incorporation of BrdU in SK-N-DZ cells ( Supplementary  Fig. 4g ) and also inhibited cell growth in all of the MYCN-amplified neuroblastoma cells tested (Fig. 3d-g and Supplementary Fig. 4h) .
In contrast to mutated-TP53-containing SK-N-DZ cells, TP53-proficient IMR-5 cells induced poly(ADP-ribose) polymerase 1 (PARP1) cleavage after treatment with P22077 ( Supplementary Fig. 4i) , suggesting that HAUSP inhibition can destabilize N-Myc, as well as active p53-mediated responses, in TP53-proficient cells. As expected, p53 is indeed stabilized in LAN-1 neuroblastoma cells (WT TP53) after treatment with P22077 (Supplementary Fig. 4j) . Although N-Myc levels are markedly reduced after the same treatment, the MDM2 inhibitor Nutlin-3a affected the stability of only p53 but not N-Myc (Supplementary Fig. 4j) . To further validate the specificity of HAUSP-mediated regulation on N-Myc, we examined the effects of the HAUSP inhibitor on neuroblastoma cell lines expressing mutated TP53 and lacking N-Myc, namely SK-N-AS and NB-16 ( Supplementary  Fig. 4k ). Treatment with P22077 failed to induce any obvious effects on cell growth in SK-N-AS and NB-16 cells (Fig. 3h,i and Supplementary  Fig. 4h ). Finally the treatment with the HAUSP inhibitor suppressed colony formation in all of the MYCN-amplified cells tested, whereas no obvious effects were observed in the MYCN non-amplified context (Fig. 3j) . These data collectively demonstrate that HAUSP inhibition is very effective in suppressing the growth of neuroblastoma cells by destabilizing N-Myc protein.
To assess the function of HAUSP in the pathogenesis of human neuroblastoma, we analyzed gene expression profiles from a cohort of 250 neuroblastoma primary tumors 30 . The levels of HAUSP (USP7) were significantly increased from patients with high-risk (MYCN-amplified and MYCN non-amplified) neuroblastoma as compared to patients categorized as low risk (stage 1) (P = 1.38 × 10 −7 ) (Supplementary Fig. 5a ). Using three independent databases, we demonstrate that USP7 expression was prognostic for disease outcome in neuroblastoma; patients with elevated USP7 mRNA levels showed significantly shorter overall survival as compared to patients bearing tumors that express lower levels of USP7 transcript ( Fig. 4a and Supplementary Fig. 5b) . To determine whether USP7 expression correlates with N-Myc function in patient tumor samples, we quantified N-Myc transcriptional activity by studying the expression of an N-Myc-specific signature in each sample 31 . The correlation between USP7 expression and the N-Myc signature (Online Methods) is significantly higher than the correlation between USP7 expression and MYCN mRNA expression (P = 0.004), which is reminiscent of the correlation of MYCN expression to N-Myc activity ( Fig. 4b and Supplementary Fig. 5c ), further validating the conclusion that HAUSP regulates N-Myc stability, and thereby N-Myc activity, in human neuroblastoma. The same trend was observed using three different MYCN signatures (Supplementary Table 1) . As a further control, six N-Myc-specific transcriptional targets from the core signature were confirmed to be downregulated after P22077 treatment in IMR-5 cells (Supplementary Fig. 5d) .
These results prompted us to test the therapeutic effects of HAUSP inhibitors, using a kidney implantation xenograft mouse model of neuroblastoma 32 . Luciferase-expressing SK-N-DZ cells were injected into the left kidney and monitored for tumor growth; 14 d after injection, the cohort was randomized into two treatment groups, vehicletreated mice and P22077-treated mice. Mice tolerated the daily intraperitoneal injection (20 mg per kg body weight (mg/kg)) regimen for 15 d, as no weight loss or other health problems were observed during treatment or after full necropsies (Supplementary Fig. 6a) . Similarly, WT mice that were treated with the same daily dose for a 1-month period did not show any obvious signs of weight loss, lethargy or microscopic tissue damage (Supplementary Fig. 6b,c) . Tumor-bearing mice receiving the HAUSP inhibitor had a significantly lower tumor weights (day 15), as compared to those from with vehicletreated mice (P < 0.005) (Fig. 4c,d) . Furthermore, immunohistological analysis showed that although HAUSP levels were unaffected after P22077 treatment, N-Myc levels markedly decreased in the treated tumors, with an observable reduction in the proliferation marker Ki67 ( Fig. 4e and Supplementary Fig. 6f) . Moreover, consistent results were obtained by adopting the commonly used subcutaneous xenograft system-P22077-treated SK-N-DZ tumors were significantly smaller than vehicle-treated tumors (P < 0.05), and they expressed less N-Myc and showed less Ki67 staining (Fig. 4f,g and Supplementary  Fig. 6f) . Notably, the MYCN-non-amplified NB-16 tumors did not show any significant differences in weight or in cellular proliferation after treatment with P22077 (Fig. 4h,i and Supplementary Fig. 6f ). These data corroborate our cell culture findings demonstrating that HAUSP inhibition regulates neuroblastoma cells by affecting N-Myc stability and activity. Collectively, our data demonstrate that HAUSP expression can function as a biomarker for poor prognosis of human neuroblastomas and that small-molecule inhibitors of HAUSP may represent a therapeutic option for MYCN-amplified neuroblastomas.
N-Myc is a short-lived protein, and its degradation is mediated by several E3 ubiquitin ligases through the ubiquitin-proteasome system 4, [33] [34] [35] [36] . Recent work has identified small molecules that increase the rate of N-Myc proteolysis by modulating the efficacy of FBXW7, a major E3 ubiquitin ligase for N-Myc 37, 38 . Modulation of the deubiquitination catalysis process may provide a quicker and more efficient way for reducing the stability of cellular proteins, as inhibition of deubiquitinase activity is a more direct approach than activating the E3 ligases that are involved in the ubiquitination of those proteins 17 . A growing number of mammalian deubiquitination enzymes that are involved in tumorigenesis, including HAUSP, has recently been revealed 8 . Previous studies have demonstrated that HAUSP inhibition leads to p53 activation via the destabilization of MDM2 (refs. 6, 18, 39, 40) . Furthermore, several studies indicate that HAUSP is a potential target for therapeutic purpose by activating p53 activities [26] [27] [28] [29] . In this study, we have identified N-Myc as a critical target for HAUSP. Like MDM2, N-Myc is overexpressed in several different types of human cancers, including neuroblastomas. Thus, HAUSP inhibitors are likely to be very effective in the treatment of human neuroblastomas through the suppression of N-Myc activities, regardless of the tumor's p53 status.
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
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oNLINe MeTHodS General methodology. Unless otherwise noted, each sample was assayed in triplicate. No samples, mice or data points were excluded from the reported analyses, except for non-engrafted xenograft mice, as indicated below. Samples were not randomized to experimental groups, except for the treatment allocation in the xenograft models, as indicated below. Analyses were not performed in a blinded manner. For xenograft models, investigators were not blinded to group allocation.
Mice. All mouse experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University Health Sciences Center under the supervision of the Institute of Comparative Medicine. The conditional knockout of Hausp was designed to flox exon 6, which upon nestin-driven Cre recombinase expression, resulted in the removal of the conserved catalytic site (Cys206). This caused a truncation in the HAUSP protein due to a frame-shift that ensured loss of all HAUSP function. All animals (both female and male) were included in the analysis, and no randomization was used. The Hausp-floxed (Hausp fl/fl ) mice were maintained on a mixed background of 129Sv and C57BL/6J, as described previously 18 . No statistical methods were used to pre-determine sample size for the analysis of Hausp fl/fl mice. For the preclinical neuroblastoma mouse model, 4-week-old female homozygous nude mice (nu/nu mice; Charles River) were housed for 1 week before being implanted with 1.7 × 10 6 SK-N-DZ cells (in 0.1 ml of PBS) expressing a luciferase construct into the left kidney. The flank muscles were then closed with absorbable sutures, and the skin was closed with staples (as in ref. 32) . After 2 weeks, engrafted tumors were visualized, and tumor-bearing mice were randomized into two groups: vehicle (DMSO)treated and P22077-treated mice. Mice with an undetectable engraftment were excluded. Mice were treated with 20 mg/kg P22077 by daily intraperitoneal injections. At day 15 after treatment, mice were killed, and the tumor-bearing kidneys and the right kidney were resected, weighed and photographed. For tumor weight, tumor-free kidney weight was subtracted from tumor-bearing kidney weight. Sample size (n = 8 per treatment group) was chosen to verify satisfactory inter-animal reproducibility. For the toxicity assay, ten 1.5-month-old WT C57BL/6J mice were separated into two groups: vehicle (DMSO)-treated and P22077-treated mice. Mice were treated with 20 mg/kg P22077 by daily intraperitoneal injections for 30 d. For subcutaneous xenografts, either SK-N-DZ cells or NB-16 cells (1.5 × 10 6 ) were mixed at a 1:1 ratio (by volume) with Matrigel (BD Biosciences) and injected subcutaneously into 5-week-old nude mice (Charles River). Two weeks after injection of NB-16 cells, and 3 weeks after injection of SK-N-DZ cells, mice were treated for 12 d with either vehicle or 20 mg/kg P22077 by daily intraperitoneal injections; investigators were not blinded to group allocation.
Embryo collection and histology. Embryos were collected from a timed pregnancy for histological analysis as described 18 . Embryos were fixed in PBS-buffered 4% paraformaldehyde solution overnight, dehydrated using ethanol and embedded in paraffin for histological analysis. Sagittal sections (6 µm) were incubated with the indicated antibodies. Horseradishperoxidase-conjugated secondary antibodies were applied per the manufacturer's recommendations. A 3,3′-diaminodbenzidine (DAB)-chromogen substrate mixture was applied. Slides were subjected to hematoxylin-eosin (H&E) staining and examined by light microscopy.
Western blot analysis.
For western blot analysis, cells were lysed in cold Flag lysis buffer (50 mM Tris-HCl (pH 7.3), 137 mM NaCl, 10 mM NaF, 0.5 mM EDTA, 1% Triton X-100, 0.2% sarkosyl, 10% glycerol and freshly supplemented protease inhibitor cocktail (Sigma)). Protein concentration was determined by the Bradford method (Bio-Rad), before equal amounts of proteins were loaded and separated in polyacrylamide gels. Nitrocellulose membranes were blocked with 5% (wt/vol) nonfat dry milk in Tris-buffered saline with Tween-20 (20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 0.1% Tween-20), incubated with the indicated primary antibodies followed by the HRP-conjugated secondary antibodies (GE Healthcare) (1:3,000; diluted in 2% (wt/vol) nonfat dry milk in Tris-buffered saline with 0.1% Tween-20), and detected on autoradiographic films after incubating with the ECL (GE Healthcare) or SuperSignal West Dura reagents (Thermo Scientific).
Antibodies. Antibodies used in this study include those specific for: N-Myc (OP-13; 1:1,000) from EMD Biosciences; p53 (DO-1; 1:1,000) and c-Myc (9E10 and C33; 1:500) from Santa Cruz Biotechnology; Ki67 (SP6; 1:500) from Lab Vision; β-actin (AC-15; 1:10,000), vinculin (V284; 1:1,000), α-tubulin (B-5-1-2; 1:4,000) and Flag (M2; 1:1,000) from Sigma; p53 (CM5; 1:1,000) from Leica Microsystems; HA (3F10; 1:1,000) and BrdU (1:500) from Roche Applied Science; GFP (JL-8; 1:1,000) from Clontech; and N-Myc (9405; 1:500), lamin B1 (12586; 1:1,000) and PARP1 (9532; 1:1,000) from Cell Signaling. For immunohistochemistry (IHC), anti-HAUSP (1:500) was from Bethyl. For western blot analyses, anti-HAUSP has been described before 5 (1:1,000 ). All primary antibodies were diluted in 5% (wt/vol) nonfat dry milk in Tris-buffered saline with 0.1% Tween-20, except for anti-N-Myc (9405), which was diluted in 5% (wt/vol) BSA in Tris-buffered saline with 0.1% Tween-20.
Immunoprecipitation. For immunoprecipitation of ectopically expressed Flag-tagged proteins, cells were lysed in BC100 buffer (20 mM Tris-HCl (pH 7.3), 100 mM NaCl, 0.2 mM EDTA, 0.2% Triton X-100, 10% glycerol and freshly supplemented protease inhibitor). Cell extracts were incubated with the monoclonal M2 (anti-Flag) antibody-conjugated agarose beads (Sigma) at 4 °C overnight. After five washes with the lysis buffer, the bound proteins were eluted with Flag peptide (Sigma) in BC100 for 2 h at 4 °C. pcDNA3.1-HA-N-Myc plasmid or the mutant constructs were cotransfected with the construct expressing HAUSP for 24 h, and the cells were lysed in BC100 buffer. Cell extracts were incubated with HA-agarose beads (Sigma) at 4 °C overnight. After five washes with the lysis buffer, the bound proteins were eluted by incubation with HA peptide (Sigma).
For endogenous immunoprecipitation assays, cells were lysed in cold BC100 buffer with sonication. 5% of the cell extract was saved as the input, and the rest was incubated with either the HAUSP-specific antibody or with control IgG at 4 °C overnight. A/G PLUS agarose beads (Santa Cruz Biotechnology) were then added for 2 h at 4 °C. After five washes with the lysis buffer, the bound proteins were eluted by boiling with SDS sample buffer.
For cell-based deubiquitination assays, Flag-N-Myc or Flag-c-Myc, and HA-HIS-ubiquitin, were cotransfected with an empty vector or a vector expressing HAUSP (WT or CS) for 36 h. Cells were lysed in BC100 buffer and an M2 (anti-Flag) immunoprecipitation was performed as describe above. For the deubiquitination assay with HAUSP inhibitor (either P5091 or P22077), 8 h before harvesting the samples, the HAUSP inhibitor, or DMSO (for controls), were added at the indicated doses.
Glutathione-S-transferase (GST) pulldown. The protein products from the pcDNA3.1-Flag-N-Myc plasmid or the pcDNA3.1-Flag-HAUSP constructs were purified under highly stringent conditions (BC300). Purified N-Myc was incubated with either purified GST alone or purified GST-HAUSP. Purified HAUSP was incubated with either purified GST alone or purified GST-N-Myc. 20 µl GST slurry beads was added in BC100 buffer at 4 °C overnight with gentle rotation. The GST beads were washed four times with BC100 buffer and eluted with 40 µl binding buffer plus 20 mM reduced glutathione for 2 h, with gentle rotation. Half of the eluate was resolved on a 4-20% SDS-PAGE gel and detected by western blot analysis.
Plasmids, cell culture and transfection. N-Myc expression vectors were constructed by polymerase chain reaction (PCR) amplification from the pGEM7Z(+)-pTH-N-Myc vector (Addgene plasmid 35416) and subcloned into either a pCIN4-Flag-HA expression vector or a pcDNA3.1 vector (Invitrogen). All HA-N-Myc deletion mutants were generated in pcDNA3.1 vectors. To construct the GST-N-Myc-expressing vector, cDNA sequences corresponding to the full-length protein were amplified by PCR from other expression vectors and cloned into a pGEX (GST) vector for expression in bacteria. The plasmids expressing HAUSP and HAUSP CS (HAUSP C223S ) have been described before 5 . cDNA encoding full-length human p53 was subcloned into the pCIN4-Flag expression vector. To confirm equal amounts of transfection, a pCMV-GFP plasmid was used. transcriptional networks to infer transcription factor activity by implementing a modification of the gene set enrichment analysis (GSEA) algorithm on a single-sample level. However, instead of a newly inferred N-Myc target signature, we used a validated list of targets from the literature (Pubmed identifiers in Supplementary Table 1 ). As shown in Figure 4b and Supplementary  Figure 5c , the correlation between MYCN expression and N-Myc activity in the cohort of MYCN-amplified neuroblastoma samples is 0.62, whereas the correlation between MYCN and USP7 expression is 0.36. Furthermore, the correlation between USP7 expression and N-Myc activity is 0.61 (highlighted in Supplementary Table 1 ). This result suggests that changes in USP7 expression can explain N-Myc activity changes that cannot be explained by N-Myc expression. To calculate the significance of the difference between two correlation coefficients, we applied the Fisher's transformation of r to z-score. This allows us to parameterize our test as the difference between two normally distributed values z 1 and z 2 , whose difference returns another z-normalized score from which an analytical p-value can be calculated. 
